Stanley Hazen

Stanley Hazen M.D., PhD Chair, Department of Cardiovascular & Metabolic Sciences; Co-section head, Preventive Cardiology & Rehabilitation; Director, Center for Microbiome & Human Health Dr. Hazen (H-index 122) has published >425 peer-reviewed articles in basic and clinical journals alike. He has made numerous discoveries in atherosclerosis and inflammatory disease research, including chemically defining various oxidative processes operative during inflammation and atherosclerosis, and both the seminal discovery linking gut microbial pathways to cardiovascular disease (CVD) pathogenesis, and the development of non-lethal microbial enzyme inhibitors for the treatment of cardiometabolic diseases. His research impacts clinical practice, and both lays the foundation for FDA-cleared diagnostic tests in use worldwide, and ongoing CVD drug development efforts. Dr. Hazen is a member of the National Academy of Medicine, and a fellow of the American Association for the Advancement of Science.